These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21792317)

  • 1. The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine.
    Ahmad EI; Gawish HH; Al Azizi NM; Elhefni AM
    Onco Targets Ther; 2011; 4():115-21. PubMed ID: 21792317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Impact of K-RAS Mutations in Adult Acute Myeloid Leukemia Patients Treated with High Dose Cytarabine.
    Ahmad EI; Gawish HH; Al-Azizi NM; El-Hefni AM
    J Egypt Natl Canc Inst; 2009 Dec; 21(4):343-50. PubMed ID: 21415871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
    Neubauer A; Maharry K; Mrózek K; Thiede C; Marcucci G; Paschka P; Mayer RJ; Larson RA; Liu ET; Bloomfield CD
    J Clin Oncol; 2008 Oct; 26(28):4603-9. PubMed ID: 18559876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study.
    Chen G; Yang J; Cao F; Zhou W; Gong D; Liu L; Zhou D
    Ann Transl Med; 2022 Aug; 10(16):858. PubMed ID: 36111020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Clinical Efficacy of Cytarabine with Different Regimens in Postremission Consolidation Therapy for Adult t(8;21) AML Patients: A Multicenter Retrospective Study in China.
    Gong D; Li W; Hu LD; Shen JL; Fang MY; Yang QM; Wang HX; Ke XY; Chen HR; Wang Z; Liu H; Liu F; Ma YG; Wang JW; Li HH; Wang QS; Jing Y; Gao XN; Dou LP; Li YH; Luo JM; Yu L
    Acta Haematol; 2016; 136(4):201-209. PubMed ID: 27640088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia.
    Marrero RJ; Wu H; Cao X; Parcha PK; Elsayed AH; Inaba H; Kuo DJ; Degar BA; Heym K; Taub JW; Lacayo N; Pui CH; Ribeiro RC; Rubnitz JE; Pounds SB; Lamba JK
    Clin Cancer Res; 2024 Oct; 30(19):4388-4396. PubMed ID: 39078289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
    Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X
    Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia.
    Neubauer A; Dodge RK; George SL; Davey FR; Silver RT; Schiffer CA; Mayer RJ; Ball ED; Wurster-Hill D; Bloomfield CD
    Blood; 1994 Mar; 83(6):1603-11. PubMed ID: 8123851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
    Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of RAS gene mutations in cytogenetically normal de novo acute myeloid leukemia patients reveals some novel alterations.
    Akram AM; Chaudhary A; Kausar H; Althobaiti F; Abbas AS; Hussain Z; Fatima N; Zafar E; Asif W; Afzal U; Yousaf Z; Zafar A; Harakeh SM; Qamer S
    Saudi J Biol Sci; 2021 Jul; 28(7):3735-3740. PubMed ID: 34220225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy.
    Seymour JF; Juneja SK; Campbell LJ; Ellims PH; Estey EH; Prince HM
    Leukemia; 1999 Nov; 13(11):1735-40. PubMed ID: 10557046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
    Heuser M; Smith BD; Fiedler W; Sekeres MA; Montesinos P; Leber B; Merchant A; Papayannidis C; Pérez-Simón JA; Hoang CJ; O'Brien T; Ma WW; Zeremski M; O'Connell A; Chan G; Cortes JE
    Ann Hematol; 2021 May; 100(5):1181-1194. PubMed ID: 33740113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK).
    Fopp M; Fey MF; Bacchi M; Cavalli F; Gmuer J; Jacky E; Schmid L; Tichelli A; Tobler A; Tschopp L; Von Fliedner V; Gratwohl A
    Ann Oncol; 1997 Mar; 8(3):251-7. PubMed ID: 9137794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of assessing cytogenetic and molecular risk factors in acute myeloid leukemia therapy.
    Coles EC; Colita A; Momanu R; Berbec N; Ivanescu AM; Oprea M; Jardan D; Jardan C; Arghir A; Coriu D; Lupu AR
    J Med Life; 2012; 5(Spec Issue):36-43. PubMed ID: 31803284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients.
    Dennis M; Thomas IF; Ariti C; Upton L; Burnett AK; Gilkes A; Radia R; Hemmaway C; Mehta P; Knapper S; Clark RE; Copland M; Russell N; Hills RK
    Blood Adv; 2021 Dec; 5(24):5621-5625. PubMed ID: 34597366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
    Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
    Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.
    Klein K; Kaspers G; Harrison CJ; Beverloo HB; Reedijk A; Bongers M; Cloos J; Pession A; Reinhardt D; Zimmerman M; Creutzig U; Dworzak M; Alonzo T; Johnston D; Hirsch B; Zapotocky M; De Moerloose B; Fynn A; Lee V; Taga T; Tawa A; Auvrignon A; Zeller B; Forestier E; Salgado C; Balwierz W; Popa A; Rubnitz J; Raimondi S; Gibson B
    J Clin Oncol; 2015 Dec; 33(36):4247-58. PubMed ID: 26573082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML.
    de Nully Brown P; Hoffmann T; Hansen OP; Boesen AM; Grønbaek K; Hippe E; Jensen MK; Thorling K; Storm HH; Pedersen-Bjergaard J
    Leukemia; 1997 Jan; 11(1):37-41. PubMed ID: 9001416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
    Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
    Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.